Document is current
Any future updates will be listed below
-
Authors
Mengel, A.
Ulm, L.
Hotter, B.
Harms, H.
Piper, S. K.
Grittner, U.
Montaner, J.
Meisel, C.
Meisel, A.
Hoffmann, S.
-
Funding
Funding for this research was provided by:
Bundesministerium für Forschung und Technologie (01EO0801)
Deutsche Forschungsgemeinschaft (Exc257)
FP7 Ideas: European Research Council (201024)
Siemens Healthcare Diagnostics
Open Access Publishing Fund of University of Tübingen (none)
Universitätsklinikum Tübingen (2459-0-0)
- License Information
-
More Information
Article History
Received: 1 February 2018
Accepted: 23 June 2019
First Online: 3 July 2019
Ethics approval and consent to participate
: Ethics approval was given by the Berlin Ethics Committee Charité – Universitätsmedizin Berlin (EA1/216/09) and Barcelona Ethics Committee Hospital Vall d’Hebron Barcelona (No.199 25/05/2012) as umbrella approvals that covered all participating sites in Germany and Spain, respectively. All patients or their legal representatives gave written informed consent in accordance with the Declaration of Helsinki. Proxy-consent was necessary if the patient could not consent due to aphasia or reduced level of consciousness. These criteria were approved by the local ethics committee.
: Not Applicable.
: Christian and Andreas Meisel have issue of a patent on anti-infective and immunomodulatory agents used for preventive antibacterial therapy after stroke (EP1480646). As one of the co-authors, Andreas Meisel, is a section editor of this journal. The other authors report no conflict of interest.This study was supported by Siemens Healthcare Diagnostics (collection of data).
